hVIVO (LON:HVO) Trading Up 4.6% - What's Next?

Shares of hVIVO plc (LON:HVO - Get Free Report) shot up 4.6% on Wednesday . The company traded as high as GBX 12.50 ($0.17) and last traded at GBX 11.77 ($0.16). 5,325,780 shares were traded during mid-day trading, an increase of 46% from the average session volume of 3,635,481 shares. The stock had previously closed at GBX 11.25 ($0.15).

Analyst Ratings Changes

Separately, Shore Capital restated a "buy" rating on shares of hVIVO in a report on Friday, May 30th.

hVIVO Stock Down 4.3%

The stock has a fifty day moving average price of GBX 15.58 and a two-hundred day moving average price of GBX 17.20. The company has a market cap of £77.83 million, a P/E ratio of 4.54 and a beta of 0.97. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16.

hVIVO (LON:HVO - Get Free Report) last issued its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. On average, research analysts expect that hVIVO plc will post 1.5492958 EPS for the current year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.